Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRN017
MIFTS: 47

Coronary Thrombosis

Categories: Blood diseases, Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Coronary Thrombosis

About this section

MalaCards integrated aliases for Coronary Thrombosis:

Name: Coronary Thrombosis 12 54 43 15 17 71
Coronary Artery Thrombosis 12

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:11847
MeSH 43 D003328
SNOMED-CT 67 398274000
ICD10 32 I22
UMLS 71 C0010072
Sources

Summaries for Coronary Thrombosis

About this section
MalaCards based summary : Coronary Thrombosis, also known as coronary artery thrombosis, is related to cardiogenic shock and heparin-induced thrombocytopenia. An important gene associated with Coronary Thrombosis is PLAT (Plasminogen Activator, Tissue Type), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Folate Metabolism. The drugs Clopidogrel and Ticagrelor have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 74 Coronary thrombosis is defined as the formation of a blood clot inside a blood vessel of the heart. This... more...

Sources

Related Diseases for Coronary Thrombosis

About this section

Diseases related to Coronary Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 388)
# Related Disease Score Top Affiliating Genes
1 cardiogenic shock 30.7 PLAT CRP
2 heparin-induced thrombocytopenia 30.6 SERPINC1 F3
3 anterolateral myocardial infarction 30.4 PLAT ACE
4 catastrophic antiphospholipid syndrome 30.3 SERPINE1 F3
5 aspirin resistance 30.3 PTGS2 ITGB3
6 ischemia 30.3 SELP PLAT GP1BA ACE
7 inferior myocardial infarction 30.3 PLG PLAT
8 angina pectoris 30.2 PLAT F3 CRP ACE
9 hemophilia a 29.8 VWF F7 F3
10 thrombophilia due to thrombin defect 29.8 SERPINE1 SERPINC1 PLAT F3 F2
11 cardiac rupture 29.7 PLAT CRP
12 protein c deficiency 29.6 SERPINE1 SERPINC1 F2
13 protein s deficiency 29.6 SERPINE1 SERPINC1 F3 F2
14 acute anterolateral myocardial infarction 29.6 PLG ITGA2B ACE
15 coronary stenosis 29.5 VWF SERPINE1 CRP ACE
16 toxic shock syndrome 29.5 SERPINC1 F3 CRP
17 hemoglobinuria 29.4 SERPINC1 SELP F2
18 paroxysmal nocturnal hemoglobinuria 29.4 SERPINC1 SELP F2
19 thrombocytopenic purpura, autoimmune 29.4 SELP ITGB3 ITGA2B GP6 GP1BA
20 antithrombin iii deficiency 29.3 SERPINC1 PLG F3 F2
21 thrombotic thrombocytopenic purpura 29.2 VWF SERPINC1 SELP PLAT ITGB3 F3
22 splenic infarction 29.2 SERPINC1 F3 F2 CRP
23 atherosclerosis susceptibility 29.2 VWF SERPINE1 SELP PLAT F3 CRP
24 polycythemia vera 29.1 VWF SELP ITGB3 F2
25 endocarditis 29.1 SERPINE1 SERPINC1 PLAT GP1BA F2 CRP
26 thrombocytosis 29.1 VWF SERPINC1 SELP F3 F2 CRP
27 homocysteinemia 29.1 VWF SERPINE1 SERPINC1 F2 CRP
28 mitral valve insufficiency 29.1 F2 CRP ACE
29 deficiency anemia 29.0 SERPINC1 SELP CRP ACE
30 hemophilia b 29.0 VWF SERPINC1 F7 F3 F2
31 infective endocarditis 29.0 SERPINE1 ITGB3 GP1BA F2 CRP
32 pneumonia 28.8 F3 F2 CRP ACE
33 arteries, anomalies of 28.7 VWF SERPINE1 PLG P2RY12 F3 CRP
34 antiphospholipid syndrome 28.5 VWF SERPINE1 SERPINC1 SELP PLAT F3
35 atrial heart septal defect 28.2 SERPINC1 PLG PLAT F3 F2 CRP
36 coronary heart disease 1 28.2 VWF SERPINE1 SELP PLAT F7 CRP
37 thrombophilia 28.1 VWF SERPINE1 SERPINC1 SELP PLAT ITGB3
38 arteriosclerosis 28.1 SERPINE1 SERPINC1 SELP ITGB3 ITGA2B GP1BA
39 migraine with or without aura 1 28.0 WDTC1 PTGS2 PLG F2 CRP ACE
40 portal vein thrombosis 28.0 SERPINE1 SERPINC1 SELP PLAT F7 F2
41 pulmonary embolism 28.0 VWF SERPINE1 SERPINC1 PLAT GP6 GP1BA
42 intermediate coronary syndrome 27.9 WDTC1 VWF SERPINC1 SELP PLG PLAT
43 acute myocardial infarction 27.8 VWF SERPINE1 SERPINC1 SELP PLG PLAT
44 purpura 27.8 VWF SERPINC1 ITGB3 ITGA2B GP1BA F3
45 intracranial embolism 27.8 SERPINC1 SELP PLG PLAT F3 F2
46 essential thrombocythemia 27.7 VWF SERPINE1 SERPINC1 SELP ITGB3 ITGA2B
47 cardiac tamponade 27.7 PLG PLAT F7 F3 F2 CRP
48 von willebrand's disease 27.6 VWF SELP PLAT P2RY12 ITGB3 GP6
49 disseminated intravascular coagulation 27.4 VWF SERPINE1 SERPINC1 PLG PLAT F7
50 lipoprotein quantitative trait locus 27.3 WDTC1 VWF SERPINE1 SELP PLG PLAT

Graphical network of the top 20 diseases related to Coronary Thrombosis:



Diseases related to Coronary Thrombosis
Sources

Symptoms & Phenotypes for Coronary Thrombosis

About this section

MGI Mouse Phenotypes related to Coronary Thrombosis:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.47 ACE CRP F2 F2R F3 F7
2 cardiovascular system MP:0005385 10.46 ACE CRP F2 F2R F3 F7
3 hematopoietic system MP:0005397 10.41 ACE F2 F2R F3 GP1BA GP6
4 immune system MP:0005387 10.35 ACE CRP F2 F2R F3 GP6
5 cellular MP:0005384 10.33 F2 F2R F3 GP1BA ITGA2B ITGB3
6 mortality/aging MP:0010768 10.33 ACE F2 F2R F3 F7 GP6
7 growth/size/body region MP:0005378 10.3 ACE F2 F2R F3 F7 ITGB3
8 integument MP:0010771 10.16 F2 F3 GP6 ITGB3 PLAT PLG
9 digestive/alimentary MP:0005381 10.14 F2 F2R ITGA2B ITGB3 PLAT PLG
10 nervous system MP:0003631 10.06 F2 F2R F3 ITGA2B ITGB3 PLAT
11 liver/biliary system MP:0005370 10.03 ACE F2R ITGB3 PLG PTGS2 SELP
12 neoplasm MP:0002006 9.91 ACE F2R F3 ITGB3 PLG PTGS2
13 reproductive system MP:0005389 9.9 ACE F2 F2R GP6 ITGA2B ITGB3
14 renal/urinary system MP:0005367 9.86 ACE F2R ITGB3 PLG PTGS2 SELP
15 respiratory system MP:0005388 9.56 F2 F3 ITGB3 PLAT PLG PTGS2
16 vision/eye MP:0005391 9.28 F2R F3 GP6 ITGB3 PLAT PLG
Sources

Drugs & Therapeutics for Coronary Thrombosis

About this section

Drugs for Coronary Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
2
Ticagrelor Approved Phase 4 274693-27-5 9871419
3
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
4
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Tirofiban Approved Phase 4 144494-65-5 60947
7 Respiratory System Agents Phase 4
8 Phosphodiesterase Inhibitors Phase 4
9 Phosphodiesterase 3 Inhibitors Phase 4
10 Anti-Asthmatic Agents Phase 4
11 Neuroprotective Agents Phase 4
12 Protective Agents Phase 4
13 Bronchodilator Agents Phase 4
14 Neurotransmitter Agents Phase 4
15 Purinergic P2Y Receptor Antagonists Phase 4
16 Immunologic Factors Phase 4
17 Immunosuppressive Agents Phase 4
18 Hypolipidemic Agents Phase 4
19 Lipid Regulating Agents Phase 4
20 Anticholesteremic Agents Phase 4
21 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
22 Antimetabolites Phase 4
23 Platelet Aggregation Inhibitors Phase 4
24 Fibrinolytic Agents Phase 4
25
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
26
tannic acid Approved Phase 3 1401-55-4
27
Chromium Approved Phase 3 7440-47-3 27668
28
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
29
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
30
Streptokinase Approved, Investigational Phase 3 9002-01-1
31
Omeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6 4594
32 Vasodilator Agents Phase 3
33 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid Phase 3
34 Analgesics, Non-Narcotic Phase 3
35 Analgesics Phase 3
36 Cyclooxygenase Inhibitors Phase 3
37 Antipyretics Phase 3
38 Antirheumatic Agents Phase 3
39 Anti-Inflammatory Agents Phase 3
40 Anti-Inflammatory Agents, Non-Steroidal Phase 3
41
Iron Approved, Experimental Phase 2 15438-31-0, 7439-89-6 27284 23925
42
Heparin Approved, Investigational Phase 2 9005-49-6 46507594 772
43
Thrombin Approved, Investigational Phase 2
44
Protein C Approved Phase 2
45 Nutmeg Approved Phase 2
46 Hematinics Phase 2
47 Ferrosoferric Oxide Phase 2
48 Pharmaceutical Solutions Phase 2
49 Parenteral Nutrition Solutions Phase 2
50 Thromboplastin Phase 2

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
2 A Clinical Evaluation of Dual Antiplatelet Therapy Duration Following Treatment With the Medtronic Endeavor Zotarolimus-eluting Coronary Stent Unknown status NCT00963781 Phase 4 Reduced duration (6 months) DAPT
3 Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT Unknown status NCT02233790 Phase 4 Ticagrelor;Clopidogrel
4 Effects of Early Atorvastatin Treatment During the Acute Phase of Stroke on Immunoinflammatory Markers and Outcome in Patients With Acute Ischemic Stroke Classified as LAAS According TOAST Classification Completed NCT02225834 Phase 4 Atorvastatin
5 Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty: The OCTAVIA Trial Completed NCT02577965 Phase 4
6 Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II) Completed NCT01166685 Phase 4
7 Treatment by Anti GP IIb/IIIa in the Setting of a Strategy of Early Coronarography to Patients With an Acute Coronary Syndrome Without ST Elevation Terminated NCT00445263 Phase 4 TIROFIBAN
8 Comparative Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control on the Gastric Lesions Induced by the Aspirin With the Low Dose Among Patients Treated With the Long Course Withdrawn NCT00713947 Phase 4 during one week for the active treatments;Pantoprazole;Placebo Formula 515
9 A Randomized Trial of Bare Metal Stent (Cronus®) - Cobalt Chromium Versus Stent Coating With Sirolimus (DES) Completed NCT01093391 Phase 3
10 Intravenous Streptokinase in Acute Myocardial Infarction Completed NCT00000507 Phase 3 streptokinase
11 Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries Completed NCT00000503 Phase 3 nitroglycerin;streptokinase
12 Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction Not yet recruiting NCT04043091 Phase 3
13 A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Veliflapon (DG-031) in Reducing the Risk of Acute Cardiovascular Events in African American Patients With Coronary Artery Disease(The LTCAD Study). Suspended NCT00353067 Phase 3 veliflapon (DG-031)
14 A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease Terminated NCT00557921 Phase 3 CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin;Plavix (clopidogrel 75 mg) and aspirin
15 ASSESSMENT OF CELLULAR INFLAMMATION FOLLOWING ACUTE MYOCARDIAL INFARCTION Application Of Ultrasmall Superparamagnetic Particles Of Iron Oxide Unknown status NCT01995799 Phase 2
16 A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome Completed NCT00619164 Phase 2 E5555;E5555;E5555;Placebo
17 A Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of Factor VIIa/Tissue Factor Inhibitor, Recombinant Nematode Anticoagulant Protein c2 (rNAPc2), in Subjects With Non-ST-Elevation Acute Coronary Syndromes - ANTHEM (Anticoagulation With rNAPc2 to Help Eliminate MACE)/TIMI 32. Amendment #3 - A Single Arm, Open-Label Study of rNAPc2 With Reduced Doses of Unfractionated Heparin Completed NCT00116012 Phase 2 rNAPc2
18 Evaluation of Neointimal Healing of Endothelial Progenitor Cell Capturing Sirolimus-Eluting (COMBO) Stent by Optical Coherence Tomography: the EGO-COMBO Pilot Study Completed NCT01274234 Phase 1, Phase 2
19 Periprocedural Myocardial Infarction: the Role of Human Neutrophil Peptide-1 to 3 Unknown status NCT02591264
20 Angiographic and Intravascular Ultrasound (IVUS) Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals Unknown status NCT00973375
21 Pilot Study Investigating the Use of a Variety of Assays to Detect Individual Response to Antiplatelet Therapy Unknown status NCT00327041
22 Assessment of Thrombotic Status in Patients With Acute Coronary Syndrome Unknown status NCT02562690
23 Study of ABSORB Stent in Acute Coronary Syndrome Unknown status NCT02071342
24 Platelets Function and Cardiovascular Events in Patients With End Stage Renal Disease Unknown status NCT00407368
25 Does the Human Gut Microbiome Serve as a Novel Personalized Therapeutic Target for Coronary Atherosclerosis? Unknown status NCT03009565
26 Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor in Patients Who Have Previously Undergone PCI Procedures and Insertion of Coronary Stents Completed NCT02297971
27 Xtractâ„¢ Aspiration Catheter Registry Study Completed NCT00349570
28 Study of Myeloid-related Protein 8/14 and Additional Biomarkers (Multi Marker Approach) for Early Diagnosis and Risk Stratification in Patients Presenting With Acute Chest Pain at the Emergency Department Completed NCT00657436
29 A Prospective Registry for the Use of CypherTM Sirolimus-Eluting Stents In Patients With Coronary Artery Disease Treated With Percutaneous Coronary Interventions at Scripps Clinic Completed NCT00714623
30 Hs-CRP as Clinical Marker of Inflammatory Atherogenic Dyslipidemia Completed NCT00169871
31 Optical Coherence Tomography in Patients With Acute Myocardial Infarction and Nonobstructive Coronary Artery Disease: OCT and CMR Study (SOFT-MI) Completed NCT02783963
32 Thrombogenic Factors and Recurrent Coronary Events Completed NCT00005358
33 Optical Frequency Domain Imaging-Quantified Intracoronary Thrombus Mass During Primary Percutaneous Coronary Intervention, Its Relationship With Antiplatelet Pretreatment Effect And Its Impact On Myocardial Reperfusion Completed NCT03342521
34 Single-centre, Prospective, Randomised, Placebo-controlled, Parallel-group Design to Determine the Cholesterol-lowering Efficacy of Lactobacillus Plantarum ECGC 13110402 in Normal to Mildly Hypercholesterolaemic Adults Completed NCT03263104
35 Thrombotic, Inflammatory & Gene Markers of CVD in Women Completed NCT00006539
36 Mechanisms of Very Late Bioresorbable Scaffold Thrombosis Assessed by Optical Coherence Tomography: Insights From the International INVEST Registry Completed NCT03180931
37 Prospective Evaluation of Acetyl-Coenzyme A Carboxylase Phosphorylation State in Platelets in Atherothrombotic Coronary Artery Disease. Completed NCT03034148
38 Etiology of Myocardial Injury Following Non-cardiac Surgery - a Prospective Clinical Trial Recruiting NCT03317561
39 Clinical Trial on Safety and Efficacy of Drug-coated Balloon in Treatment of Coronary Bifurcation Lesions Recruiting NCT03223974
40 Long Term Clinical Outcomes of Angioplasty With Paclitaxel-coated Balloon Only Strategy for Coronary de Novo Lesions: a Single Center Registry Study Recruiting NCT04022200
41 Diagnostic Accuracy of Electrocardiogram for Acute Coronary Occlusion Recruiting NCT04022668
42 EKG Criteria and Identification of Acute Coronary Occlusion Recruiting NCT03863327
43 Pathology and Pathogenesis of Cardiac Injury in COVID-19 Infections in Humans Recruiting NCT04367792
44 Proteomic and Lipidomic Profiling of Coronary Thrombus in Acute Myocardial Infarction Recruiting NCT03731884
45 The Cholesterol-lowering Efficacy of Probiotic Lactobacillus Plantarum ECGC 13110402 (LPLDL®) in Hypercholesterolemic Adults Active, not recruiting NCT03540108
46 Predictive Value of HAS-BLED and CHA2DS2-Vasc Scores for Clinical Outcome After PCI Not yet recruiting NCT04047199
47 CAOCT Study is a Prospective, Multi-centre, Single Cohort, Diagnostic Accuracy Study, Planned to Include 131 Patients in About 3 European Countries After Successful Return of Spontaneous Circulation After Out of Hospital Cardiac Arrest Not yet recruiting NCT04431661

Search NIH Clinical Center for Coronary Thrombosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
Tenecteplase
Urokinase

Cochrane evidence based reviews: coronary thrombosis

Sources

Genetic Tests for Coronary Thrombosis

About this section
Sources

Anatomical Context for Coronary Thrombosis

About this section

MalaCards organs/tissues related to Coronary Thrombosis:

40
Heart, Endothelial, Testes, Neutrophil, Smooth Muscle, Kidney, Myeloid
Sources

Publications for Coronary Thrombosis

About this section

Articles related to Coronary Thrombosis:

(show top 50) (show all 2335)
# Title Authors PMID Year
1
[Annexin A5 inhibits homocysteine-induced tissue factor expression and activity in vascular smooth muscle cells]. 54 61
20137335 2009
2
Atherothrombosis: role of tissue factor; link between diabetes, obesity and inflammation. 54 61
17249334 2007
3
Rapid release of active tissue factor from human arterial smooth muscle cells under flow conditions. 61 54
16528008 2006
4
Detection of von Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction. 61 54
16377278 2006
5
[Regulatory effect of IL-10 on expression of tissue factor induced by IL-6 in peripheral blood mononuclear cells]. 61 54
15972146 2005
6
Angiographic demonstration of coronary dethrombosis with eptifibatide. 61 54
15156011 2004
7
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. 61 54
14963043 2004
8
How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. 61 54
12808446 2003
9
Plasminogen activator inhibitor-1, which is released from blood product transfusions, might be associated with (sub)acute thrombosis after coronary dilatation and stenting: a case report. 61 54
12644882 2003
10
Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death. 61 54
11028489 2000
11
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly. 61 54
10928474 2000
12
Polymorphisms in the 5' regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Témoins de l'Infarctus du Myocarde. Paris Thrombosis case-control Study. 54 61
10712418 2000
13
The PlA2 polymorphism of the platelet glycoprotein IIIA gene as a risk factor for acute renal allograft rejection. 61 54
10589700 1999
14
Glycoprotein IIIa Pl(A) polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. 61 54
10521390 1999
15
Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. 61 54
10199872 1999
16
Association between the ACE genotype and coronary artery disease. Insights from studies on restenosis, vasomotion and thrombosis. 61 54
9796837 1998
17
Coronary thrombosis associated with antithrombin-III deficiency. 61 54
9327319 1997
18
Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. 54 61
9012634 1997
19
Identification of active tissue factor in human coronary atheroma. 61 54
8822973 1996
20
Enhanced platelet aggregability under high shear stress after treadmill exercise in patients with effort angina. 61 54
8725732 1996
21
Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis. 61 54
8735626 1996
22
Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. 54 61
7641354 1995
23
Novel antithrombotic approaches to coronary artery disease. 61 54
7863968 1995
24
Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. 61 54
8026028 1994
25
Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. 54 61
1451271 1992
26
Reduced synthesis of tissue plasminogen activator by vascular endothelium during acute myocardial infarction. 54 61
1497553 1992
27
Role of heparin in coronary thrombolysis. 61 54
1555478 1992
28
Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis. 61 54
1606285 1992
29
Thrombolytic effects of a novel modified tissue plasminogen activator, E6010, on coronary thrombosis in the pig. 61 54
1513078 1992
30
[Takotsubo syndrome during SARS-CoV-2 pneumonia: a possible cardiovascular complication]. 61
32425184 2020
31
Recurrent Type III Kounis Syndrome: Will Anti-Immunoglobulin E Drug Be Another Option? 61
32536377 2020
32
Optical coherence tomography guided treatment avoids stenting in an antiphospholipid syndrome patient: A case report. 61
32548174 2020
33
Multivessel coronary thrombosis in a patient with COVID-19 pneumonia. 61
32374373 2020
34
Spontaneous Coronary Thrombosis in a Young Patient With Nephrotic Syndrome. 61
32245566 2020
35
Massive coronary thrombosis caused primary percutaneous coronary intervention to fail in a COVID-19 patient with ST-elevation myocardial infarction. 61
32473051 2020
36
A Rare Case of Coronary Artery Thrombosis in a Patient With Recently Diagnosed Giant Cell Arteritis: Is Anticardiolipin Antibody Involved? 61
32542132 2020
37
Simultaneous intracoronary, intracardiac, and pulmonary venous thrombosis. 61
32423703 2020
38
Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia. 61
32469847 2020
39
COVID-19 complicated by acute myocardial infarction with extensive thrombus burden and cardiogenic shock. 61
32427416 2020
40
Prognosis of Type 2 Myocardial Infarction Patients Implanted With a Prophylactic Defibrillator (from the Very-High-Rate Registry). 61
31932082 2020
41
Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy. 61
32067865 2020
42
Acute ST-Elevation Myocardial Infarction Caused by Simultaneous Occlusion of Two Culprit Arteries. 61
32377488 2020
43
Diagnosis and prognosis of myocardial infarction in a patient without obstructive coronary artery disease during bronchoscopy: a case study and literature review. 61
32316919 2020
44
Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event. 61
32144037 2020
45
Effect of remote ischaemic conditioning on platelet reactivity and endogenous fibrinolysis in ST-elevation myocardial infarction- a substudy of the CONDI-2/ERIC-PPCI randomised controlled trial. 61
32163139 2020
46
Diagnosis of coronary microvascular dysfunction in the clinic. 61
31904824 2020
47
Acute coronary syndrome in an adolescent with aortic root replacement (Bentall). 61
32019612 2020
48
Thrombotic Thrombocytopenic Purpura: What an Intensive Care Unit Doctor Needs to Know. 61
32313734 2020
49
Biomechanical Stress Profiling of Coronary Atherosclerosis: Identifying a Multifactorial Metric to Evaluate Plaque Rupture Risk. 61
31005542 2020
50
Incidence, characteristics and outcomes in very young patients with ST segment elevation myocardial infarction. 61
31524668 2020
Sources

Variations for Coronary Thrombosis

About this section
Sources

Expression for Coronary Thrombosis

About this section
Search GEO for disease gene expression data for Coronary Thrombosis.
Sources

Pathways for Coronary Thrombosis

About this section

Pathways related to Coronary Thrombosis according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 12.91 VWF SERPINE1 SERPINC1 SELP PLG PLAT
2
Folate Metabolism 1
Show member pathways
 12.24 SERPINE1 PTGS2 PLG PLAT F7 F2
3
Cell surface interactions at the vascular wall 65
Show member pathways
 12.1 SELP ITGB3 GP6 F2
4
ECM-receptor interaction 36
Show member pathways
 12.05 VWF ITGB3 ITGA2B GP6 GP1BA
5
Platelet activation 36
12.02 VWF P2RY12 ITGB3 ITGA2B GP6 GP1BA
6
Complement and coagulation cascades 36 1
11.97 VWF SERPINE1 SERPINC1 PLG PLAT F7
7
Adhesion 4
11.93 SERPINE1 PLG ITGB3 F3
8
Integrin alphaIIb beta3 signaling 65
Show member pathways
 11.79 VWF ITGB3 ITGA2B GP1BA F2
9
Hematopoietic cell lineage 36
11.76 ITGB3 ITGA2B GP1BA
10
Angiogenesis (CST) 4
11.76 VWF PTGS2 ITGB3 F3
11
Formation of Fibrin Clot (Clotting Cascade) 65
Show member pathways
 11.57 VWF SERPINE1 SERPINC1 PLG PLAT GP6
12
Cell adhesion_ECM remodeling 22
11.53 SERPINE1 PLG PLAT
13
Platelet Aggregation Inhibitor Pathway, Pharmacodynamics 60
11.51 VWF P2RY12 ITGB3 ITGA2B GP6 F2R
14
ECM proteoglycans 65
11.49 SERPINE1 ITGB3 ITGA2B
15
amb2 Integrin signaling 1
11.42 SELP PLG PLAT GP1BA
16
A-beta Plaque Formation and APP Metabolism 64
11.06 PLG PLAT ACE
17
Platelet Adhesion to exposed collagen 65
10.78 VWF GP6 GP1BA
18
Warfarin Pathway, Pharmacodynamics 60
10.77 F7 F2
19
Dissolution of Fibrin Clot 65
10.77 SERPINE1 PLG PLAT
20
GP1b-IX-V activation signalling 65
10.58 VWF GP1BA
Sources

GO Terms for Coronary Thrombosis

About this section

Cellular components related to Coronary Thrombosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.2 SERPINE1 SERPINC1 SELP POU2F3 PLG P2RY12
2 extracellular region GO:0005576 10.14 VWF SERPINE1 SERPINC1 PLG PLAT F7
3 extracellular exosome GO:0070062 10 VWF SERPINE1 SERPINC1 PLG PLAT ITGB3
4 extracellular space GO:0005615 9.9 SERPINE1 SERPINC1 SELP PLG PLAT GP1BA
5 external side of plasma membrane GO:0009897 9.88 SELP P2RY12 ITGA2B F2 ACE
6 blood microparticle GO:0072562 9.76 SERPINC1 PLG ITGA2B F2
7 caveola GO:0005901 9.69 PTGS2 P2RY12 F2R
8 platelet alpha granule lumen GO:0031093 9.67 VWF SERPINE1 PLG
9 cell surface GO:0009986 9.61 PLG PLAT P2RY12 ITGB3 ITGA2B GP6
10 platelet alpha granule membrane GO:0031092 9.54 SELP ITGB3 ITGA2B
11 serine-type peptidase complex GO:1905286 9.43 F7 F3
12 collagen-containing extracellular matrix GO:0062023 9.23 VWF SERPINE1 SERPINC1 PLG PLAT F7

Biological processes related to Coronary Thrombosis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.9 VWF SERPINE1 ITGB3 ITGA2B
2 platelet degranulation GO:0002576 9.88 VWF SERPINE1 SELP PLG ITGB3 ITGA2B
3 leukocyte migration GO:0050900 9.85 SELP ITGB3 GP6 F2
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.78 SELP F2R F2
5 response to wounding GO:0009611 9.74 VWF F2R F2
6 platelet aggregation GO:0070527 9.73 P2RY12 ITGB3 ITGA2B GP1BA
7 platelet activation GO:0030168 9.7 VWF P2RY12 ITGB3 GP6 GP1BA F2R
8 positive regulation of blood coagulation GO:0030194 9.67 SERPINE1 F7 F2R F2
9 blood coagulation, intrinsic pathway GO:0007597 9.65 VWF GP1BA F2
10 fibrinolysis GO:0042730 9.65 SERPINE1 PLG PLAT GP1BA F2
11 hemostasis GO:0007599 9.65 VWF SERPINC1 PLG P2RY12 GP6 GP1BA
12 negative regulation of fibrinolysis GO:0051918 9.63 SERPINE1 PLG F2
13 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.62 ITGB3 CRP
14 regulation of blood coagulation GO:0030193 9.62 SERPINC1 GP1BA F2R F2
15 positive regulation of leukocyte migration GO:0002687 9.61 SELP ITGA2B
16 positive regulation of positive chemotaxis GO:0050927 9.59 F7 F3
17 negative regulation of blood vessel diameter GO:0097756 9.58 PTGS2 CRP
18 negative regulation of lipid storage GO:0010888 9.58 ITGB3 CRP
19 thrombin-activated receptor signaling pathway GO:0070493 9.56 GP1BA F2R
20 smooth muscle cell migration GO:0014909 9.54 PLAT ITGB3
21 trans-synaptic signaling by BDNF, modulating synaptic transmission GO:0099183 9.52 PLG PLAT
22 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.51 F7 F3
23 blood coagulation, extrinsic pathway GO:0007598 9.49 F7 F3
24 blood coagulation GO:0007596 9.4 VWF SERPINC1 PLG PLAT P2RY12 ITGB3

Molecular functions related to Coronary Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 WDTC1 VWF SERPINE1 SERPINC1 SELP PTGS2
2 peptidase activity GO:0008233 9.83 PLG PLAT F7 F2 ACE
3 endopeptidase activity GO:0004175 9.63 PLG F7 ACE
4 signaling receptor binding GO:0005102 9.63 SERPINE1 PLG PLAT F7 F2R F2
5 serine-type peptidase activity GO:0008236 9.56 PLG PLAT F7 F2
6 fibrinogen binding GO:0070051 9.37 ITGB3 ITGA2B
7 serine-type endopeptidase activity GO:0004252 9.35 PLG PLAT F7 F3 F2
8 thrombin-activated receptor activity GO:0015057 9.32 GP1BA F2R
9 protease binding GO:0002020 9.02 VWF SERPINE1 SERPINC1 ITGB3 F3
Sources

Sources for Coronary Thrombosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....